{"name":"Enyo Pharma","slug":"enyo-pharma","ticker":"","exchange":"","domain":"enyopharma.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-01-08","type":"trial","source":"Business Wire","summary":"ENYO Pharma Announces Completion and Topline Data From Phase 2 Alpestria-1 Clinical Study in Alport Syndrome Demonstrating Vonafexor Reverses Kidney Function Decline and Has Sustained Therapeutic Bene","headline":"ENYO Pharma Announces Completion and Topline Data From Phase 2 Alpestria-1 Clinical Study in Alport Syndrome Demonstrati","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOcVRDbnd1RTlTVXN0SWpjcThHWkdIZENOMnUtbVdUMllpdWNIc2VtSTY4clBhbEFqNWx3dWFXeTBoWXdZWjJKbUJ5R0RsbEJBb25Hd0ZPRFlzWENHRTZlaURpSEFZQmozY2M5T2RDNFRwYUdHQlpiNWdJdXZHRmhxdlhpSmVRcW5lZm5JbFhqZFVDQnZkb2xyMGlIWQ?oc=5","date":"2025-09-15","type":"pipeline","source":"PharmTech.com","summary":"Competition in MASH Is Heating Up as GLP-1s Gate-Crash the Party - PharmTech.com","headline":"Competition in MASH Is Heating Up as GLP-1s Gate-Crash the Party","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxPT1hJbko2RXF1aGNyYXJraFlKdHdpRnA3WlZhSTZqcDJ2RGd6cUpxVnAxeFlIQm5LNDBRdEZjS3k3NUVxZ0oxVnlld09fem83eW0yNmtGV1diVHRBMGg4aHdLcDhBOVFSLVd6T1RSYnlKZ3R2TzBabnJWdjdHci12eURxSXBTbVQwQTl5RjZEYjRudW9QbE1CaGxZUUFJYTF3dzVVbTVta3lCZUhqMkpIZkhaN1JWZEdIZlpUbUI1WjJmQmhWUVItWlczUTFneUhlNGpCU3FyVVd5Y3NvRXQwLTQ3SzEzWERhTVlVRnRwSVAzOTJBc2thcTVNSFZFZTYxN2NTSTV1aG5zMDJnMHVYTlBqa1hjbUo0NV9waUtuc1gtbHY2aEFJdUkzMFZ5WkM2aUdmRzVUSQ?oc=5","date":"2025-06-12","type":"trial","source":"BioSpace","summary":"ENYO Pharma Announces Completion of Series C Financing With Vesalius Biocapital and Continued Progress of Its ALPESTRIA-1 Clinical Phase 2 Study in Alport Syndrome Patients - BioSpace","headline":"ENYO Pharma Announces Completion of Series C Financing With Vesalius Biocapital and Continued Progress of Its ALPESTRIA-","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxPX243Y3JxQ2w1ZGhqcTJIQkNiSmFFSHgxaWVMZTQ4dE8tRFctWVBHVWxPaWNkSFZibFhpaG5jSzd0WjktNVl5c2I3bFh6b0g0clpBb2tQNGpodTFsQXNRclcxY3FpU1o1X0hjaGdwTzJ0WG1aUWZESGREdENIOFRJUHpvTFJtS3puX1VZcEh6cE96NWtTb3JjbDEwLTY1blZWWkl6QnZEdXNVNkp2Y05DM0VOUk5OQjY3VEkyVzMzU1lxaDg0dUlvOUlvX1g0cUhnRkNxVFpRUDlKcHdKeVM2eTJ5cGJDWkpoRDZaU2VubFR0QWhLWHJzNHRSbzQ1U0dwT2VqYg?oc=5","date":"2024-02-05","type":"pipeline","source":"Dentons","summary":"Dentons advises Bpifrance Large Ventures in a 39M€ Series C financing round of Lyon-based biotech company ENYO Pharma - Dentons","headline":"Dentons advises Bpifrance Large Ventures in a 39M€ Series C financing round of Lyon-based biotech company ENYO Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE1LeC1lOUF4QkV0TGliMGdaNlFVMlM5YzEwaFJqbFNWSnlpNTNzNEQ4eF80X3hoNEt6UU5kdXdpYjZMMmtMNDB2eUg0WWdnQnk0Qm1XQkNOMHk1aWF3alhCYUYzdm55T1RWUmdyOGxoNDZuNmpmb2tCclJlZkhpSDA?oc=5","date":"2024-01-04","type":"pipeline","source":"Pharmaceutical Technology","summary":"ENYO Pharma raises €39m Series C funding to advance Vonafexor - Pharmaceutical Technology","headline":"ENYO Pharma raises €39m Series C funding to advance Vonafexor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgJBVV95cUxOeUNtdmpxSGpOc2hyT3hWYmlFWm50RHNsbG04SmdwcDY0ZGllRXotcFhoQndhLXFqbjlSUFV4UWNOQTk5Z1dOLVZVdGtmbmJ2STNxZHRKc0N2S2dWTEtiZ2l3Y2g4NHZORlZtNDNMRFNvRUxmZC1TeVo4cWF6eEZRbENzbHpNZ0ZfYXp4dWFsODhOUnZiOUZEQkM4Tzg2V3BXbThHTFM3NGxxZ3lmdHNRdnc4YXFQUzNQN2VNaE8xblltOUFZd2VzeDFTdmNHMGpacE8xc3lkS1FUcDZFLVpJcnBoSWNZRXFpRG5SWUlWVmg2UmJrTEZzZzdlZTlKSEVhdUZIWHJLcEdldTcyLUxWY1V5eFpnNHVaSjJLUXRvWmhGaE9hLWVGcTkwbkVUeHZBdXFqdGdVbVFiakVQZFJjclNR?oc=5","date":"2024-01-03","type":"regulatory","source":"Business Wire","summary":"ENYO Pharma Announces a €39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Trial for Patients With Alport Syndrome - Business Wire","headline":"ENYO Pharma Announces a €39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Tria","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxOUVdEVUFyaExBV2FnNXVROFdaXzNsN01xZzgxVnFRTHhIWVdxM24tWVNubmwyaGRvdEJqbW15Ql90TS1hNXNwd2FkOHRtV0h0NUp0SWoyTHhONjF3eGpfVTBiUVJLbWFldGl6SERMeFFwYWxBZHNKcUozQXJUR0dpWVpBWXExOVV2U0hZM0swY1RXWlVpMDFQTEpEdHFqLTd3d0p3Vi10b0tBMy1vT2ZKQzZYaVBDcXJYTjUyVHozWkxCMGtkV0RpTEVTYWhuZDVvY2ZJLVExQV91LWt3VDVzWDVpV3FWWmV5Zm5UR0ZodTFCWnRKRGhBUDdYZlpINXVVa2pDUVBmbmhfUmc?oc=5","date":"2024-01-03","type":"regulatory","source":"BioSpace","summary":"ENYO Pharma Announces a €39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Trial for Patients With Alport Syndrome - BioSpace","headline":"ENYO Pharma Announces a €39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Tria","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTFBjei1sTUlnUS1NeExzMU1ZRjhXQTAxaXVuMG14WUlOSHN4eVJ1TktzS0ZfSnZMaEdCQlZkenlIWUdBNUhiNEhDcWNiT3NZRzhQNWh0WlpBSUh6c2hLemNKU2loQzJDYXByaGM2cE9ITTZ2dw?oc=5","date":"2022-06-24","type":"pipeline","source":"Labiotech.eu","summary":"French Biotech Raises €40M to Fight Hepatitis B and NASH - Labiotech.eu","headline":"French Biotech Raises €40M to Fight Hepatitis B and NASH","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOeWppRnBtVGVBMEFtNDdXaWVQNmNpMzZ3QWVXbFY1aWtMMEItXzRUWUg2WC1OMWR1XzNtdmFPVVpyZWVHLTk4WldSVWdUZGFsWXZKRE1yRFh3NXpSM1lpY3czcno3RnRZNlhhb25CcTJ6TW5lZlBqM09ZOWtRRWFuNktCRjUxUllDRC16WGtPdUlmODBpSFJ1Y3hfR2FWYTBHRl8xbWRjSDg?oc=5","date":"2021-08-04","type":"pipeline","source":"European AIDS Treatment Group","summary":"ENYO Pharma provides updates on vonafexor for the treatment of hepatitis B - European AIDS Treatment Group","headline":"ENYO Pharma provides updates on vonafexor for the treatment of hepatitis B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE1OWUwwR1ZVLXRYdGRzRksxelRKRURsZ2ZIakhkUkZtQktaN1k0UW5ZOEtXSU1xbUJMdG9OeUdQUkNyX1FvVVVITUcwMlB3RFJ6ajNIQ1pTbXJZRE5nbjVNS2trSFNaVFE4WTA3RUNSWEdFczZrMFE?oc=5","date":"2021-07-29","type":"trial","source":"Clinical Trials Arena","summary":"ENYO Pharma’s Vonafexor meets endpoints in Phase IIa NASH trial - Clinical Trials Arena","headline":"ENYO Pharma’s Vonafexor meets endpoints in Phase IIa NASH trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPVm56WDdFNmtWazVZQUhHRlF0YzBQMTY4aGhnNUFodDVCRjRzRGdBQ0MyRnZTUXBQMlJsNU5vWkg0NUhIZUJHdWlHZGdxcVVHQndzRjJyNVBHVkIyWGRoNWRudGlHa3V0ZF9fRGM2YTc2Z3Q5ZVNwYkI4SUJQNXNaVGx6Y24tbndXVHA3TmtOZGFSeG03RUh3YzhsTlJxOEtkVmtTWnJ2c3FvNWUyXzFON24yMHlTV1N3c3NPTkpidDRGLXZOTFE?oc=5","date":"2021-07-28","type":"pipeline","source":"Fierce Biotech","summary":"Enyo Pharma's NASH results show boost in kidney function, differentiating vonafexor from busy field - Fierce Biotech","headline":"Enyo Pharma's NASH results show boost in kidney function, differentiating vonafexor from busy field","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE12RWw5dHM4M2NhS1luT3BHQWpvcXJiRXJIVllORkFhQ2xiYWx6b1RyMWZ0bkVUc2hhT1pzYUVMYVp6TER3S25TaFFuVXIwVWh2MVNIWmdkckREa0taUkc4VjBHeVZTdlhCbGM3aXd3?oc=5","date":"2019-07-10","type":"pipeline","source":"Labiotech.eu","summary":"The Top 10 Biotechs You’ll Find in Lyon - Labiotech.eu","headline":"The Top 10 Biotechs You’ll Find in Lyon","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}